Typ 2-Diabetes - Intensives Monitoring und Titrierung der Insulindosis ermöglichen HbA_1c-Werte unter 7%

Literatur

• 1 European Diabetes Policy Group. Diabetic Medicine. 1999, 16, 716-730. 
• 2 American Association of Clinical Endocrinologists. Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management - 2002 Update. Endocrine Pract. 2002, 8 (Suppl. 1), 40-82. 
• 3 American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 28 (Suppl 1), 5-36. 
• 4 Linn T . Nuber U . Axel M . et al. . The Role of Titration Enforcement for the Treat-To-Target Concept with Add-on Insulin Therapy in Patients with Type 2 Diabetes. Presented at the 41^st Annual Meeting of the European Association for the Study of Diabetes (EASD), Athens, Greece 10-15 September, 2005. 
• 5 Richter M . Schiwietz J . Reinhard Z . et al. . Insulin Glargine Improves Metabolic Parameters in Well Controlled Patients with Type 2 Diabetes Previously on an Intensive Conventional Therapy (ICT) with NPH Insulin. Presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD), Athens, Greece 10-15 September, 2005. 

1 Lantus®, Sanofi-Aventis Deutschland GmbH